Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

This study has been completed.
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Corporation Identifier:
First received: June 26, 2013
Last updated: January 26, 2015
Last verified: January 2015

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy

Condition Intervention Phase
Diabetic Nephropathy
Drug: MT-3995-Low
Drug: MT-3995-High
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy

Resource links provided by NLM:

Further study details as provided by Mitsubishi Tanabe Pharma Corporation:

Primary Outcome Measures:
  • Frequency and nature of treatment-emergent adverse events and serious adverse events. [ Time Frame: 20 weeks ] [ Designated as safety issue: Yes ]
  • Plasma concentrations of MT-3995 and its major metabolite [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

Enrollment: 51
Study Start Date: July 2013
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MT-3995-Low
MT-3995-Low Dose
Drug: MT-3995-Low
Experimental: MT-3995-High
MT-3995-High Dose
Drug: MT-3995-High
Placebo Comparator: Placebo
Drug: Placebo


Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with Type 2 diabetes mellitus and diabetic nephropathy, who have been treated with a stable dose of angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin II receptor blocker (ARB)
  • Glycosylated haemoglobin (HbA1c) ≤10.5%
  • Subject with albuminuria

Exclusion Criteria:

  • History of Type 1 diabetes, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy.
  • Serum potassium level <3.5 or >5.0 mmol/L
  • Subjects who had acute kidney injury within 3 months prior to baseline or have undergone hemodialysis at any time prior to randomisation
  • Subjects with clinically significant hypotension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01889277

Koukan Hospital
Kawasaki, Kanagawa Pref., Japan
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
Study Director: Masaomi Nangaku, Professor Division of Nephrology and Endocrinology University of Tokyo School of medicine
Study Director: Kazuoki Kondou, Adviser Mitsubishi Tanabe Pharma Corporation
  More Information

No publications provided

Responsible Party: Mitsubishi Tanabe Pharma Corporation Identifier: NCT01889277     History of Changes
Other Study ID Numbers: MT-3995-J03
Study First Received: June 26, 2013
Last Updated: January 26, 2015
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Diabetic Nephropathy

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urologic Diseases processed this record on October 02, 2015